Z1TS34 Stock Overview
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.54 |
| 52 Week High | US$70.00 |
| 52 Week Low | US$47.10 |
| Beta | 0.94 |
| 1 Month Change | 3.45% |
| 3 Month Change | -11.23% |
| 1 Year Change | 7.69% |
| 3 Year Change | -4.64% |
| 5 Year Change | 53.13% |
| Change since IPO | 60.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| Z1TS34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | -8.3% | 0.7% | 2.1% |
| 1Y | 7.7% | -22.3% | -5.4% |
Return vs Industry: Z1TS34 exceeded the BR Pharmaceuticals industry which returned -22.3% over the past year.
Return vs Market: Z1TS34 exceeded the BR Market which returned -5.4% over the past year.
Price Volatility
| Z1TS34 volatility | |
|---|---|
| Z1TS34 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BR Market | 9.5% |
| 10% least volatile stocks in BR Market | 3.0% |
Stable Share Price: Z1TS34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: Z1TS34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 13,800 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Zoetis Inc. Fundamentals Summary
| Z1TS34 fundamental statistics | |
|---|---|
| Market cap | R$414.80b |
| Earnings (TTM) | R$14.28b |
| Revenue (TTM) | R$53.17b |
29.0x
P/E Ratio7.8x
P/S RatioIs Z1TS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Z1TS34 income statement (TTM) | |
|---|---|
| Revenue | US$9.26b |
| Cost of Revenue | US$2.72b |
| Gross Profit | US$6.54b |
| Other Expenses | US$4.05b |
| Earnings | US$2.49b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 70.64% |
| Net Profit Margin | 26.86% |
| Debt/Equity Ratio | 138.3% |
How did Z1TS34 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield32%
Payout RatioDoes Z1TS34 pay a reliable dividends?
See Z1TS34 dividend history and benchmarks| Zoetis dividend dates | |
|---|---|
| Ex Dividend Date | Apr 16 2025 |
| Dividend Pay Date | Jun 09 2025 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 83 days |
Does Z1TS34 pay a reliable dividends?
See Z1TS34 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 16:00 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zoetis Inc. is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Douglas Tsao | Barclays |